Insight Molecular Diagnostics (IMDX) Total Non-Current Liabilities (2019 - 2026)

Insight Molecular Diagnostics (IMDX) has 8 years of Total Non-Current Liabilities data on file, last reported at $13.3 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 71.99% year-over-year to $13.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.3 million (down 71.99% YoY) and the FY2025 annual result came in at $13.8 million, up 14.62% from the prior year.
• Total Non-Current Liabilities slipped to $13.3 million in Q1 2026 per IMDX's latest filing, from $13.8 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $81.9 million in Q1 2022, with the low at $8.5 million in Q2 2025.
• Average Total Non-Current Liabilities over 5 years is $27.6 million, with a median of $17.9 million recorded in 2022.
• Year-over-year, Total Non-Current Liabilities jumped 464.85% in 2022 and sank 84.27% in 2025.
• Insight Molecular Diagnostics' Total Non-Current Liabilities stood at $17.9 million in 2022, then slumped by 49.0% to $9.1 million in 2023, then jumped by 31.62% to $12.0 million in 2024, then rose by 14.62% to $13.8 million in 2025, then slipped by 3.29% to $13.3 million in 2026.
• Business Quant data shows IMDX's Total Non-Current Liabilities at $13.3 million in Q1 2026, $13.8 million in Q4 2025, and $9.2 million in Q3 2025.